On March 16, 2021, Fujian Haixi New Drug Creation Co., Ltd. received the "Drug Registration Certificate" issued by the State Drug Administration.
This product is used to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD) and maintenance dialysis. Our company has passed the examination and approval of the fourth company of the same variety in China according to the standards of 4 categories of chemical drugs (it is regarded as passing the consistency evaluation). This is also the second MAH "Drug Registration Certificate" obtained by our company, which will have a positive impact on improving the company's popularity and the development of the company's drug business.
In the future, the company will continue to adhere to the mission of "letting Chinese people use the best medicine", and develop more high-quality and affordable drugs to help a healthy China.
